←
Uriel Suárez17,790 posts
Uriel Suárez avatar✓

Uriel Suárez ✓

@UsuarezMD

⚕️medical school @UIS | internal medicine @Medicina_UdeA | hematology @Hospital_FJD • “IACH News of the Week” 🗞️ @TheIACH •••

◷ Joined May 2013▧ 2,261 Photos and videos
Uriel Suárez avatar
Uriel Suárez@UsuarezMD·Nov 5

Happy to share our clinical case “IMAGES IN HAEMATOLOGY” of @BrJHaem 🗞️ << Primary bone lymphoma with cervical compression mimicking solitary osseous plasmacytoma>> • Key point: bone lymphoma may have a clinical presentation indistinguishable from that of solitary plasmacytoma or metastatic carcinoma, and clinicians should suspect it in cases of persistent axial bone pain even without B-type symptoms. @FabioTorressav @PaolaPizano @DraLPardoG #lymphoma #lymsm Link: onlinelibrary.wiley.com/doi/… @DrAEvens

Post attachment
Sven Borchmann avatar
⟳ Uriel Suárez retweeted
Sven Borchmann@svenborchmann·56m

Adding CD28 costimulation to glofitamab without new safety signals is the encouraging part for me. Did the benefit stay mostly in follicular lymphoma, as in the ASH 2024 escalation data, or did the aggressive histologies catch up with longer follow-up?

EBMT avatar
⟳ Uriel Suárez retweeted
EBMT@TheEBMT·5h

CAR T-cell therapy expands beyond cancer to autoimmune diseases 🔬 💬 @RaffaellaGrecoM discusses the 2026 update of the EBMT – @ISCTglobal – @JACIE_EBMT practice harmonisation and consensus recommendations, developed with @eular_org and @ECTRIMS representatives, supporting safe clinical practice. 📃 Access the article in @TheLancetRheum: thelancet.com/journals/lanrh… #CARTcell #CARTcellTherapy #CellTherapy #AutoimmuneDisease #PatientCare

2:15
IACH avatar
⟳ Uriel Suárez retweeted
IACH@TheIACH·5h

🎙️ What to Expect in Multiple Myeloma at #ASH26? Looking at the abstracts already available, one message is clear: 
we are witnessing a fundamental transformation in how we treat myeloma. We are moving beyond conventional combinations of: 
• Proteasome inhibitors 
• Immunomodulatory agents 
• Monoclonal antibodies Toward a landscape increasingly dominated by: 
• T-cell redirection 
• Multi-antigen targeting 
• Highly personalized immunotherapy The question is no longer just: 
How deep a response can we achieve? It is becoming: 
How do we translate these remarkable responses into durable survival, while minimizing toxicity and preserving patients' quality of life? In our new podcast, we highlight 5 major developments we believe deserve particular attention at #ASH26 in New Orleans. 🎧 Listen here: on.soundcloud.com/PR2CKPiJ8h… #MultipleMyeloma @Mohty_EBMT

Post attachment
Uriel Suárez avatar
Uriel Suárez@UsuarezMD·5h

Great Job @OpenMedInsights @OpenMedicineHQ team! An excellent resource for the medical community. Algorithms covering various specialties, ranging from basic to advanced topics. Highly recommended!!!

0:59
Open Medicine Insights avatar
⟳ Uriel Suárez retweeted
Open Medicine Insights@OpenMedInsights·22h

· Open Medicine Algorithm Spotlight · Hypernatremia Diagnostic Evaluation: Stepwise Clinical and Laboratory Approach (by @iamnephrologist) @OpenMedicineHQ Key points: - Concordance among sodium, measured osmolality, glucose, and measurement method distinguishes true hypertonic hypernatremia from analytical or osmolar discordance. - Neurologic findings reflect the severity and rapidity of hypertonicity, while hemodynamic and physical findings determine whether urgent volume resuscitation is required. - Classification as hypovolemic, euvolemic, or hypervolemic is a standard organizing step that narrows the balance of total-body water and sodium. ** Hypovolemic hypernatremia reflects combined sodium and water loss with proportionally greater water loss; orthostasis, tachycardia, low venous pressure, and prerenal kidney injury are supportive. ** Euvolemic hypernatremia usually represents relatively pure water loss through renal or extrarenal routes without clinically apparent sodium depletion or overload. ** Volume overload accompanying hypernatremia should prompt evaluation for hypertonic sodium administration, ingestion, dialysis-related loading, or less commonly mineralocorticoid-mediated retention. LIVING algorithm link: myopenmedicine.com/algorithm… #OpenMedicine #Nephrology #NephTwitter #KidneyDisease #NephPearls #InternalMedicine @OpenMedKate @scserendipity1

Mohamad Mohty avatar
⟳ Uriel Suárez retweeted
Mohamad Mohty@Mohty_EBMT·22h

What to Expect in Multiple Myeloma at #ASH2026 ? The #ASH26 Meeting in New Orleans promises to be particularly exciting for the multiple myeloma community. And looking at the abstracts already available, one message is becoming increasingly clear: we are witnessing a fundamental transformation in how we treat myeloma. We are moving beyond conventional combinations of proteasome inhibitors, immunomodulatory agents, and moAbs toward a therapeutic landscape increasingly dominated by T-cell redirection, multi-antigen targeting, and highly personalized immunotherapy. But the fundamental question is no longer simply: How deep a response can we achieve? It is becoming: How can we translate these remarkable responses into durable survival, while minimizing toxicity and preserving patients’ quality of life? In this @TheIACH podcast, we would like to highlight five major developments that we believe deserve particular attention at #ASH26. soundcloud.com/cme-congresse…